253 related articles for article (PubMed ID: 22154841)
1. Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice.
Shahnazari M; Dwyer D; Chu V; Asuncion F; Stolina M; Ominsky M; Kostenuik P; Halloran B
Bone; 2012 Mar; 50(3):628-37. PubMed ID: 22154841
[TBL] [Abstract][Full Text] [Related]
2. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
[TBL] [Abstract][Full Text] [Related]
3. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao J; Venton L; Sakata T; Halloran BP
J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
[TBL] [Abstract][Full Text] [Related]
4. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
5. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
6. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
[TBL] [Abstract][Full Text] [Related]
7. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
[TBL] [Abstract][Full Text] [Related]
8. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
9. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
Christiansen P
APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
[TBL] [Abstract][Full Text] [Related]
10. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
Kassem M
APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
[TBL] [Abstract][Full Text] [Related]
11. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.
Wang L; Liu S; Quarles LD; Spurney RF
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587
[TBL] [Abstract][Full Text] [Related]
12. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
13. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
[TBL] [Abstract][Full Text] [Related]
14. Physiological function of the angiotensin AT1a receptor in bone remodeling.
Kaneko K; Ito M; Fumoto T; Fukuhara R; Ishida J; Fukamizu A; Ikeda K
J Bone Miner Res; 2011 Dec; 26(12):2959-66. PubMed ID: 21887703
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a diminished maturation of preosteoblasts into osteoblasts during aging in rats: an ultrastructural analysis.
Roholl PJ; Blauw E; Zurcher C; Dormans JA; Theuns HM
J Bone Miner Res; 1994 Mar; 9(3):355-66. PubMed ID: 8191929
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of the mediator of catabolic bone remodeling RANKL in the bone marrow environment link chronic heart failure with osteoporosis.
Leistner DM; Seeger FH; Fischer A; Röxe T; Klotsche J; Iekushi K; Seeger T; Assmus B; Honold J; Karakas M; Badenhoop K; Frantz S; Dimmeler S; Zeiher AM
Circ Heart Fail; 2012 Nov; 5(6):769-77. PubMed ID: 22936827
[TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
Okamoto M; Murai J; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
[TBL] [Abstract][Full Text] [Related]
18. Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio.
Rucci N; Rufo A; Alamanou M; Teti A
J Cell Biochem; 2007 Feb; 100(2):464-73. PubMed ID: 16927271
[TBL] [Abstract][Full Text] [Related]
19. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
20. Chronic low dose tumor necrosis factor-α (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts.
Gilbert LC; Chen H; Lu X; Nanes MS
Bone; 2013 Sep; 56(1):174-83. PubMed ID: 23756233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
